Key result
Hypertrophic cardiomyopathy was associated with more frequent postexercise troponin rises than in mutation carriers (18% vs 4%, p=0.01), with HighT2 on CMRi as an independent predictor (OR 7.9).
Why the study?
The interplay between exercise and disease development in HCM remains uncertain.
Does exercise induce myocardial injury (troponin rise) in patients with hypertrophic cardiomyopathy compared to mutation carriers without hypertrophy?
Observational (n=180)
Yes
Does exercise induce myocardial injury (troponin rise) in patients with hypertrophic cardiomyopathy compared to mutation carriers without hypertrophy?
Answers are grounded in this paper and cite their sources.
HighT2 on CMRi identifies a vulnerable subset of HCM patients prone to exercise-induced myocardial injury, suggesting an active disease state.
Objective Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of myocardial injury in hypertrophic cardiomyopathy (HCM). The interplay between exercise and disease development remains uncertain in HCM. We sought to assess the occurrence of postexercise troponin rises and its determinants. Methods Multicentre project on patients with HCM and mutation carriers without hypertrophy (controls). Participants performed a symptom limited bicycle test with hs-cTnT assessment pre-exercise and 6 hours postexercise. Pre-exercise CMRi was performed in patients with HCM to assess measures of hypertrophy and myocardial injury. Depending on baseline troponin (< or >13 ng/L), a rise was defined as a >50% or >20% increase, respectively. Results Troponin rises occurred in 18% (23/127) of patients with HCM and 4% (2/53) in mutation carriers (p=0.01). Comparing patients with HCM with and without a postexercise troponin rise, maximum heart rates (157±19 vs 143±23, p=0.004) and maximal wall thickness (20 mm vs 17 mm, p=0.023) were higher in the former, as was the presence of late gadolinium enhancement (85% vs 57%, p=0.02). HighT2 was seen in 65% (13/20) and 19% (15/79), respectively (p<0.001). HighT2 was the only independent predictor of troponin rise (adjusted odds ratio 7.9; 95% CI 2.7 to 23.3; p<0.001). Conclusions Postexercise troponin rises were seen in about 20% of patients with HCM, almost five times more frequent than in mutation carriers. HighT2 on CMRi may identify a group of particularly vulnerable patients, supporting the concept that HighT2 reflects an active disease state, prone to additional injury after a short episode of high oxygen demand.
No takes yet. Share an insight, caveat, or question.
Cramer et al. (2020) conducted an observational in Hypertrophic cardiomyopathy (n=180). Hypertrophic cardiomyopathy vs. Mutation carriers without hypertrophy was evaluated on Postexercise troponin rise (>50% or >20% increase depending on baseline) (p=0.01). Hypertrophic cardiomyopathy was associated with more frequent postexercise troponin rises than in mutation carriers (18% vs 4%, p=0.01), with HighT2 on CMRi as an independent predictor (OR 7.9).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: